COMPUTEX
3.6.2021 10:35:08 CEST | Business Wire | Press release
According to Gartner, by 2023, one-third of companies that have implemented IoT will also have implemented AI in conjunction with at least one IoT project. Data generated from IoT devices will be integrated in various vertical applications and eventually be applied to smart factories, smart healthcare, smart transportation, and smart cities. The first two sessions of COMPUTEX Forum organized by TAITRA, "AIoT Evolution" and "AI Empowerment,” were held on June 2. Top speakers from Micron Technology, Intel, Supermicro, NVIDIA, NXP Semiconductors, Arm, Delta Electronics, and Check Point Software were among the lineup to deep dive into the infinite possibilities of AIoT and AI.
Micron Technology: Driving AI innovation with storage in the new era of data intensive computing
President and CEO of Micron Technology Sanjay Mehrotra pointed out that the world is at the dawn of a new age of data intensive computing. AI and 5G are the two major drivers of this age. With the rapid growth of AI applications, accompanied by numerous challenges, Micron Technology will continue to build a reliable, systematic infrastructure based on memory and storage for a better AI future.
Intel: Embracing infinite computing possibilities with next-gen AI processor
Nash Palaniswamy, Vice President of Intel’s Sales and Marketing Group and General Manager of AI, HPC, Datacenter Accelerators Solutions and Sales, addressed the possibilities of 3rd Gen Intel Xeon Scalable Processor. The latest generation of Xeon is capable of fulfilling AI and high-performance computing needs. Supported by close partnerships and deep integrations with the world’s software leaders and solution providers, Intel delivers fast, consistent, and secure solutions that people trust.
Supermicro: Meeting demands for innovations with an array of products and solutions
Supermicro President and CEO Charles Liang stated that Supermicro will continue to meet customer demand in terms of AI, 5G, and cloud solutions through its leading technology, innovation, high quality, and serviceability. Supermicro will also push forward the development of technology with its partners through collaborations.
NVIDIA: Igniting Industrial Revolution 4.0 with AI
According to Jerry Chen, NVIDIA Head of Global Business Development for Manufacturing and Industrials, AI is the most impactful general-purpose technology, and it will be at the heart of advanced technologies such as 5G, HPC, AIoT, and robotics, propelling industry development and transformation.
NXP Semiconductors: Accelerating Secure Intelligent Edge with New Era of Edge Computing Started
Kurt Sievers, President and CEO of NXP Semiconductors, indicated that AIoT devices are changing the way people live. While it creates great user experience, it is imperative to fully protect data and realize a secure intelligent edge. NXP Semiconductors will also continue to enable a safer and smarter world through breakthrough innovations.
Arm: Accelerating ubiquitous intelligence
Rene Haas, President of Arm IP Products Group, discussed the increasing global demand for computing. The new Armv9 architecture is effective in addressing demanding AI/ML workloads while delivering enhanced security. The next-gen architecture outlines the roadmap for the next decade of computing.
Intelligence-driven manufacturing for advancing into Industry 4.0
According to Dr. Steven Chen, Leader of Intelligent Mobile Machine Cluster, Delta Research Center of Delta Electronics, manufacturers must continue to improve their capabilities to achieve “Manufacturing on Demand.” By adopting design that incorporate standardized, modular and intelligent units, machines can be more scalable and flexible to production changes, as well as data collection & analysis and AI adoption and upgrade, accelerating the progress of an Intelligence-driven manufacturing.
Check Point Software: Managing cybersecurity risks through AI tool
Kev Hau, Check Point Security evangelist, office of the CTO, shared his insights on the trend of cybersecurity in the new normal. AI, machine learning, and big data analytics are all revolutionizing cybersecurity. The machine-learning algorithm of AI is capable of predicting unknown threats in a much broader scope and providing cybersecurity specialists a quick response with increasing accuracy and precision.
AI is reshaping the world. With the democratization of related technologies and AIoT applications, COMPUTEX aims to explore more business opportunities with its global partners.
- All sessions are available online from now: https://virtual.computextaipei.com.tw/events/
- Register for free:
https://virtual.computextaipei.com.tw/
For more information: https://virtual.computextaipei.com.tw/events/
#########
For more information:
COMPUTEX : https://www.computextaipei.com.tw/
InnoVEX : https://www.innovex.com.tw/
About COMPUTEX
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Virtual
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX,Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnovexVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.
Explore #COMPUTEXVirtual now at https://virtual.computextaipei.com.tw/ .
About TAITRA
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005420/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom